Anji Pharma Provides Update on ANJ900 Pivotal Program
businesswire.com
news
2022-06-02 00:00:00

June 02, 2022 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anji Pharma, an emerging global medicines company, today announced successful completion of a pharmacokinetic (PK) study of ANJ900 in healthy Chinese volunteers to enable initiation of a pivotal clinical program in China later this year. ANJ900, a delayed-release formulation of metformin, is currently being studied in an ongoing multinational Phase 3 trial, DREAM-T2D, in type 2 diabetes (T2D) patients with normal, mild, and moderate chronic kidney disease (CKD stages 1-3B).
